Engage Therapeutics

About:

Engage Therapeutics is a clinical stage pharmaceutical company with a deep-seated passion in epilepsy.

Website: https://engagetherapeutics.com/

Top Investors: Adage Capital Management, Lumira Ventures, LifeSci Venture Partners, Granite Point Capital, TPG Biotech

Description:

Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company’s lead investigational drug is Staccato® alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures. Staccato alprazolam in a Phase 2a proof of concept study demonstrated reduction of seizure in a photosensitivity model. The product will proceed into an advanced clinical setting leveraging a 505(b)(2) regulatory pathway.

Total Funding Amount:

$23.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Summit, New Jersey, United States

Founded Date:

2017-01-01

Founders:

Greg Mayes, Jouko Isojärvi

Number of Employees:

1-10

Last Funding Date:

2017-09-27

IPO Status:

Private

Industries: